Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with obesity
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
Reoperation rate · participants with obesity
1 finding from 1 review
Body‐mass index (BMI) · participants with obesity
1 finding from 1 review
Health related quality of life the Uniscale and the Symptom Distress Scale (SDS); Better indicated by lower values · participants with obesity
1 finding from 1 review
Comorbidities: diabetes · participants with obesity
1 finding from 1 review
Clinical success (absence of periapical pathology, tenderness to pressure and fistula formation) at 24 months · adults with HIV and progressive disseminated histoplasmosis
Induction: liposomal amphotericin may leads to higher clinical success compared with amphotericin deoxycholate (low certainty).
1 finding from 1 review
Death · adults with HIV and progressive disseminated histoplasmosis
Induction: liposomal amphotericin showed no clear difference in death compared with amphotericin deoxycholate (low certainty).
1 finding from 1 review
Nephrotoxicity (safety population) · adults with HIV and progressive disseminated histoplasmosis
Induction: liposomal amphotericin leads to lower safety outcomes: nephrotoxicity compared with amphotericin deoxycholate (high certainty).
1 finding from 1 review
Safety outcomes: drug discontinuation · adults with HIV and progressive disseminated histoplasmosis
It is very uncertain whether induction: liposomal amphotericin changes safety outcomes: drug discontinuation compared with amphotericin deoxycholate (very low certainty).
1 finding from 1 review
Number of women cured · women with urinary incontinence
It is very uncertain whether PFMT added to electrical stimulation changes number of women cured compared with electrical stimulation alone (excluding implanted electrodes) (very low certainty).
1 finding from 1 review
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measure of urine leakage (e.g. pad test) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found